Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 ...

Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the ...

Sage Therapeutics said its Phase 2 trial of dalzanemdor in patients with mild cognitive impairment or mild dementia due to ...

The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.

Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus ...

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...

The WAIS-IV test assesses the intellectual abilities of people aged between 16 and 90. A total of 174 participants were randomized. Based on these data, the company does not plan further clinical ...